AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E401553-T1: [Translated] ROTATION POSITION SENSOR

A robust, low cost, compact and highly accurate rotary position sensor (10) is disclosed for measuring the relative angular position (within a range ¤ 180°) of a housing (18) or stator and a rotor (14). The housing (18) carries a galvanomagnetic sensing element (80) and is adapted for fixation to a relatively fixed portion of a host system. The rotor (14) carrying a magnet (54) is disposed for rotation about a fixed axis (x) with respect to the stator (18) and is interconnected to a relatively moving portion of the host system through intermediate linkage. The magnet (54) is juxtaposed in substantially axial alignment with the galvanomagnetic sensing element (80) for magnetic interaction therewith. The housing (18) defines a cavity (76) to receive potting material (88) for encasing the galvanomagnetic sensing element (80) and an adjacent buffer cavity (126) interconnected by a weir (118), which diverts ant excess potting material into the buffer cavity (126).
Compound 525338: 2,6-Dimethylthioanisole

Chemical compound data from PubChem database. IUPAC Name: 1,3-dimethyl-2-methylsulfanylbenzene. Molecular Formula: C9H12S. Molecular Weight: 152.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528115: 2-Ethoxy-3-methyl-5-(2-methylbutyl)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 2-ethoxy-3-methyl-5-(2-methylbutyl)pyrazine. Molecular Formula: C12H20N2O. Molecular Weight: 208.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399820-T1: [Translated] EFFECTS PIGMENTS WITH GLASS SHADES CONTAINING TITANIUM OXIDE

The present invention relates to an effect pigment comprising as a substrate a glass flakes with a coating, said coating comprising at least one layer of at least one high refractive material, said material having a refractive index of at least 1.8, wherein said glass flakes comprising the following composition: n50 - 65 wt.-% silicium oxide n10 -18 wt.-% aluminium oxide n10 - 28 wt.-% calcium oxide n0.05 - 15 wt.-% titanium oxide, based on the weight of said glass flakes. The invention relates also to a method for producing the effect pigments as well as to the use of said effect pigments. The invention further relates to the use of glass flakes having a content of titanium oxide as a substrate for effect pigments.
Illinois (IL)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Illinois for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays

Background
          CMV is a major clinical problem in transplant recipients. Thus, it is important to use sensitive and specific diagnostic techniques to rapidly and accurately detect CMV infection and identify patients at risk of developing CMV disease. In the present study, CMV infection after liver transplantation was monitored retrospectively by two molecular biology assays - a quantitative PCR assay and a qualitative NASBA assay. The results were compared with those obtained by prospective pp65 antigenemia determinations.
        
        
          Materials and Methods
          87 consecutive samples from 10 liver transplanted patients were tested for CMV by pp65 antigenemia, and CMV monitor and NASBA pp67 mRNA assay.
        
        
          Results
          CMV infection was detected in all patients by antigenemia and CMV monitor, whereas NASBA assay identified only 8/10 patients with viremia. Furthermore, CMV infection was never detected earlier by molecular biology assays than by antigenemia. Only 5/10 patients with CMV infection developed CMV disease. Using a cut off value of 8 cells/50,000, antigenemia was found to be the assay that better identified patients at risk of developing CMV disease. However, the kinetics of the onset of infection detected by NASBA and CMV monitor seemed to have better identified patients at risk of developing CMV disease. Furthermore, before onset of disease, CMV pp67 mRNA was found to have similar or better negative and positive predictive values for the development of CMV disease.
        
        
          Conclusions
          The present data, suggests that the concomitant use of antigenemia and pp67 mRNA assay gives the best identification of patients at risk of developing CMV disease.
Compound 528926: Benzaldehyde, 2-hydroxy, 3-chloro-5-tert.-butyl, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: 1-(5-tert-butyl-3-chloro-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C17H30ClNO2Si2. Molecular Weight: 372.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Plasma proteins in a standardised skin mini-erosion (I): permeability changes as a function of time

Background
          A standardised technique using a suction-induced mini-erosion that allows serial sampling of dermal interstitial fluid (IF) for 5 to 6 days has been described. In the present study, we studied permeability changes as a function of time.
        
        
          Methods
          We examined IF concentrations of total protein concentration and the concentration of insulin (6.6 kDa), prealbumin (55 kDa), albumin (66 kDa), transferrin (80 kDa), IgG (150 kDa) and alpha-2-macroglobulin (720 kDa) as a function of time, using an extraction pressure of 200 mmHg below atmospheric.
        
        
          Results
          At 0 h after forming the erosion, mean total IF protein content (relative to plasma) was 26 ± 13% (SD). For the individual proteins, the relative mean concentrations were 65 ± 36% for insulin, 48 ± 12% for albumin, 30 ± 19% for transferrin, 31 ± 15%for IgG and 19.5 ± 10% for alpha-2-macroglobulin. At 24 h, the total IF protein content was higher than at 0 h (56 ± 26% vs 26 ± 13%; p < 0.05, diff: 115%), as were some of the individual protein concentrations: prealbumin (50 ± 24 vs 25 ± 13%; p < 0.05), albumin (68 ± 21 vs 48 ± 12%; p < 0.05) and IgG (55 ± 30 vs 31 ± 15%; p = 0.05). ln the interval 24 h to 96 h the concentrations were relatively unchanged.
        
        
          Conclusions
          The results indicate that fluid sampled at 0 h after forming the erosion represents dermal IF before the full onset of inflammation. From 24 h onward, the sampled fluid reflects a steady state of increased permeability induced by inflammation. This technique is promising as a tool for clinically sampling substances that are freely distributed in the body and as a model for studying inflammation and vascular permeability.
Patent AT-E400848-T1: [Translated] PROCESSING APPARATUS WITH BURST READ AND WRITE OPERATIONS

A digital signal processing system comprises a programmable processor (PROC) and a peripheral device (PD, MEM) coupled to the programmable processor via a burst generation device (BG). The processor is arranged to communicate with the peripheral device using a read operation and a write operation, respectively, on a single data element. The burst generation device (BG) groups a plurality of read operations or a plurality of write operations in a single burst read operation or a single burst write operation, respectively.
Virtual Reality - The Next Stage of Caseworker Training

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 527081: Tetratriacontane, 6,12,16-trimethyl

Chemical compound data from PubChem database. IUPAC Name: 6,12,16-trimethyltetratriacontane. Molecular Formula: C37H76. Molecular Weight: 521.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic

NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 529876: Pyrazine, 2-(2-thienylmethyl)-3,5-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 3,5-dimethyl-2-(thiophen-2-ylmethyl)pyrazine. Molecular Formula: C11H12N2S. Molecular Weight: 204.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Welfare Outcomes 2016: Report to Congress

This report to Congress provides information on the performance of states on seven national outcome categories and also includes data on contextual factors and findings of analyses conducted across states.

(PDF)

(PDF (PDF) - 4.04MB)

(PDF)

(PDF (PDF) - 1.18MB)

The PDF is best viewed in Chrome or Firefox. If using Internet Explorer (IE), please right click the link, save the file, and view it locally.

Executive Summary

Contextual FactorsState Performance on Outcome MeasuresConclusion and Recommendations for Further InvestigationChild Welfare Outcomes Data Site

Introduction to the Child Welfare Outcomes, Data, and Analysis

Outcome MeasuresContext DataData SourcesData Analyses in the ReportThe Child Welfare Outcomes Report Data Site

Chapter 1: Child Welfare Outcomes Demographic Data

National Child PopulationChildren in Foster CareFoster Care Entry RatesChildren Waiting for Adoption and Children AdoptedSummary

Chapter 2: Keeping Children Safe

Child Victims and Child FatalitiesRange of State Performance on Safety-Related Outcome MeasuresChanges Over Time in State Performance on Measures of Maltreatment Recurrence and Maltreatment of Children in Foster CareSummary of Findings Regarding Keeping Children Safe

Chapter 3: Finding Permanent Homes for Children in Foster Care

Range of Performance in Achieving Permanency for Children in Foster CareChanges Over Time in State Performance on Measures of Achieving PermanencySummary of Findings Regarding Achieving Permanency for Children in Foster Care

Chapter 4: Achieving Timely Reunifications and Adoptions for Children in Foster Care

Caseworker VisitsTimeliness of ReunificationsChanges Over Time in State Performance With Regard to Achieving Timely ReunificationsTimeliness of AdoptionsChanges Over Time in State Performance With Regard to Timeliness of AdoptionsSummary of Findings Regarding Achieving Reunifications and Adoptions in a Timely Manner

Chapter 5: Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Stable and Appropriate Placement Settings for Children in Foster CareSummary of Findings Regarding Achieving Stable and Appropriate Placements for Children in Foster Care

Chapter 6: State Comments on Performance Relevant to the Seven National Child Welfare Outcomes

Appendix A: Adoption and Safe Families Act of 1997 (Pub. L. 105—89)

Appendix B: Child Welfare Outcomes Report: Outcomes and Measures

Appendix C: Caseworker Visits

Appendix D: Child Welfare Outcomes Report: Data Sources and Elements

Appendix E: Child Maltreatment 2016: Summary of Key Findings

Appendix F: The AFCARS Report: FY 2016 Estimates

Appendix G: Data-Quality Criteria

Metadata-only record linking to the original dataset. Open original dataset below.
Virginia (VA)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Virginia for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Normal embryonic stages of the Longnose Gar,

Background
          Gaps exist in the modern literature that describes patterns of development in living groups of actinopterygian fishes. Relatively recent descriptions of development exist for the teleost fishes, bowfin, sturgeon, paddlefish and bichirs. Such literature dealing with the gars is to be found in older work, done approximately a century ago. The present study concerns the gars, of which the garpike, Lepisosteus osseus, is a representative example.
        
        
          Results
          The embryonic period of life of this fish is divided, as required for experimentation, into 34 stages, from fertilization to exhaustion of the yolk supply. Diagnostic structural characteristics are cited for each stage, and the rate of development is indicated.
        
        
          Conclusions
          Three features of development are especially noted that compare or contrast with other members of the Neopterygii, and with the Chondrostei. These are meroblastic cleavage, a well-defined yolk syncytial layer (ysl), and a pit at the posterodorsal edge of the blastoderm, which defines an overhanging dorsal lip. Meroblastic cleavage and the ysl in the garpike show an affinity to those character states in the teleosts, though not with Amia, the other neopterygian fish. The posterodorsal pit and dorsal lip are reminiscent of similar features in the Chondrostei. Lepisosteus is unique among the Neopterygii with respect to this character state. Such comparisons set the stage for a broader understanding of the mechanisms for development in these organisms, and of the evolutionary relationships between them.
Patent AT-E400728-T1: [Translated] PISTON FOR AN INTERNAL COMBUSTION ENGINE

A pivoted piston for an internal combustion engine. The piston has a pivot pin (14) and an arcuate first sealing surface 12 which describes a circumferential path about the pivot pin (14) which forms a removable and replaceable skirt to the piston. The piston also includes a second arcuate sealing surface (13) which also describes a circumferential path about the pivot pin and which is connected to the first arcuate sealing surface by a piston floor (21). The second arcuate sealing surface (13) is composed of at least two arcuate sealing components (24) which are located on a bed (20) with the components being located on the bed (20) so they will have limited transverse movement on the bed (20). The components (24) have mating faces which restrict the path of combustion gases between the mating faces. The piston further includes side seals (62) which are located in grooves (63) in the side of the piston. A restraining pin (60) assists in locating the seals (62) in the seal grooves and also closes a pressure escape path for the combustion gases. The piston further includes means to allow liquid coolant to pass through the pivot shaft 14, through liquid cooling galleries in the piston and out o the pivot shaft 14.
Hospitals

<div>[<a href='https://files.hawaii.gov/dbedt/op/gis/data/hospitals.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>Metadata</a>]  Locations of hospitals in the State of Hawaii as of November 2021.. Source:  State Department of Health, Office of Health Care Assurance (OHCA).</div><div><br /></div><div><div><font size='3'><span style='color:rgb(77, 77, 77);'>For additional information, please refer to complete metadata at <a href='https://files.hawaii.gov/dbedt/op/gis/data/hospitals.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>https://files.hawaii.gov/dbedt/op/gis/data/hospitals.pdf</a></span></font><font size='4'><font size='3'><span style='color:rgb(77, 77, 77);'> </span><span style='color:rgb(77, 77, 77); font-size:14px; background-color:rgb(255, 255, 255); font-family:monospace;'><span style='font-family:Verdana;'>or contact </span></span><span style='color:rgb(77, 77, 77);'>Hawaii Statewide GIS Program, Office of Planning and Sustainable Development, State of Hawaii; PO Box 2359, Honolulu, Hi. 96804; (808) 587-2846; email: </span><a href='mailto:gis@dbedt.hawaii.gov' style='color:rgb(33, 117, 155);' target='_blank' rel='nofollow ugc noopener noreferrer'>gis@hawaii.gov</a><span style='color:rgb(77, 77, 77);'>; Website: </span><a href='https://planning.hawaii.gov/gis' target='_blank' rel='nofollow ugc noopener noreferrer'>https://planning.hawaii.gov/gis</a><span style='color:rgb(77, 77, 77);'>.</span></font><span><br /></span></font></div></div>
Respiratory Virus Dashboard Metrics

__Note__: On April 30, 2024, the Federal mandate for COVID-19 and influenza associated hospitalization data to be reported to CDC’s National Healthcare Safety Network (NHSN) expired. Hospitalization data beyond April 30, 2024, will not be updated on the Open Data Portal. Hospitalization and ICU admission data collected from summer 2020 to May 10, 2023, are sourced from the California Hospital Association (CHA) Survey. Data collected on or after May 11, 2023, are sourced from CDC's National Healthcare Safety Network (NHSN).

Data is from the California Department of Public Health (CDPH) Respiratory Virus State Dashboard at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Respiratory-Viruses/RespiratoryDashboard.aspx.

Data are updated each Friday around 2 pm.

For COVID-19 death data: As of January 1, 2023, data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2023–Present. Prior to January 1, 2023, death data was sourced from the COVID-19 case registry. The change in data source occurred in July 2023 and was applied retroactively to all 2023 data to provide a consistent source of death data for the year of 2023. Influenza death data was sourced from the California Department of Public Health, California Comprehensive Death File (Dynamic), 2020–Present.

COVID-19 testing data represent data received by CDPH through electronic laboratory reporting of test results for COVID-19 among residents of California. Testing date is the date the test was administered, and tests have a 1-day lag (except for the Los Angeles County, which has an additional 7-day lag). Influenza testing data represent data received by CDPH from clinical sentinel laboratories in California. These laboratories report the aggregate number of laboratory-confirmed influenza virus detections and total tests performed on a weekly basis. These data do not represent all influenza testing occurring in California and are available only at the state level.
Acetylcysteine

Acetylcysteine is a prescription medication used as a mucolytic to help loosen mucus in lung conditions and as an antidote for acetaminophen overdose. Available as a 20% solution (200 mg/mL) for oral or inhalation use, it's manufactured by Fresenius Kabi USA, LLC under ANDA203853. This information was generated using AI and is provided for informational and research purposes only.
2022 Mental Health Client-Level Data (MH-CLD) Detailed Tables

The Annual Detailed Tables provide data on race, ethnicity, sex, and age of clients served. The MH-CLD data set can also observe these demographic categories across National Outcome Measures (NOMs) which include stability in housing/residential status, adult employment, and access to services/capacity. These tables provide a comprehensive set of national, subgroup, and state-level data on key characteristics of individuals receiving treatment in the 2022 reporting year along with their mental health diagnoses and co-occurring disorders.
Compound 529227: N,O-Bis(tert-butyldimethylsilyl)hydroxylamine

Chemical compound data from PubChem database. IUPAC Name: 2-[[[tert-butyl(dimethyl)silyl]oxyamino]-dimethylsilyl]-2-methylpropane. Molecular Formula: C12H31NOSi2. Molecular Weight: 261.55. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.